Candong, Princess Nadia .

HRN: 23-34-82  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/02/2024
CEFTRIAXONE 1G (VIAL)
06/02/2024
07/07/2024
IV
425mg
Q12
AGE
Waiting Final Action 
06/03/2024
CLOXACILLIN 250MG/5ML, 60ML SUSPENSION (BOT)
06/03/2024
06/10/2024
ORAL
2.5ml
Q8
Bacterial Skin Infection
Waiting Final Action 
06/03/2024
MUPIROCIN 2%, 15G (TUBE)
06/03/2024
06/10/2024
TOPICAL
Pea-sized
Q8
Bacterial Skin Infection
Waiting Final Action 
06/03/2024
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
06/03/2024
06/10/2024
TOPICAL
Pea-sized
Q8
Bacterial Skin Infection
Waiting Final Action 
06/03/2024
OXACILLIN 500MG (VIAL)
06/03/2024
06/10/2024
IV
200
Q6h
Bacterial Skin Infection
Waiting Final Action 
06/03/2024
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
06/03/2024
06/10/2024
ORAL
2ml
Q12
Bacterial Skin Infection
Waiting Final Action 
06/06/2024
METRONIDAZOLE 125MG/5ML, 60ML (BOT)
06/06/2024
06/13/2024
PO
4ml
Q8hours
Infectious Diarrhea
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: